1. Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients With Coronavirus Disease 2019.
- Author
-
Zeng, Qing-Lei, Yu, Zu-Jiang, Gou, Jian-Jun, Li, Guang-Ming, Ma, Shu-Huan, Zhang, Guo-Fan, Xu, Jiang-Hai, Lin, Wan-Bao, Cui, Guang-Lin, Zhang, Min-Min, Li, Cheng, Wang, Ze-Shuai, Zhang, Zhi-Hao, and Liu, Zhang-Suo
- Subjects
- *
COVID-19 , *VIRAL shedding , *SARS-CoV-2 , *CONVALESCENT plasma , *CORONAVIRUS disease treatment , *VIRAL pneumonia , *VIRAL physiology , *IMMUNIZATION , *RNA , *RETROSPECTIVE studies , *CATASTROPHIC illness , *TREATMENT effectiveness , *EPIDEMICS , *VIRAL antibodies , *POLYMERASE chain reaction - Abstract
Currently, coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been reported in almost all countries globally. No effective therapy has been documented for COVID-19, and the role of convalescent plasma therapy is unknown. In the current study, 6 patients with COVID-19 and respiratory failure received convalescent plasma a median of 21.5 days after viral shedding was first detected, all tested negative for SARS-CoV-2 RNA within 3 days after infusion, and 5 eventually died. In conclusion, convalescent plasma treatment can end SARS-CoV-2 shedding but cannot reduce the mortality rate in critically ill patients with end-stage COVID-19, and treatment should be initiated earlier. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF